UNSPSC 51413913: Iproxamine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C18H29NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83L52U43TX, chemically known as carbonic acid, 4-(2-(dimethylamino)ethoxy)-2-methyl-5-(1-methylethyl)phenyl 1-methylethyl ester, hydrochloride; but more generally known as iproxamine hydrochloride, which bears US NIH Compound Identifier 172982. Most nations, for tariff and trade purposes, schedule iproxamine hydrochloride under HS 29221980 and SITC 51461.

As of Q4 2014, IPROXAMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Iproxamine hydrochloride bears US NLM identifiers UMLS ID C1881264 and NCI Concept Code C65957. SMILES: CC1CC(C(CC1OC(=O)OC(C)C)C(C)C)OCCN(C)C.CL.

UNSPSC 51413913 Iproxamine hydrochloride is a Commodity code capturing individual pharmaceutical products supplied to state and local health systems, emergency services, and benefit programs. State and local governments procure under this code primarily through emergency medical services procurement (EMS medications for fire and rescue departments), state pharmacy benefit programs, and cooperative purchasing alliances serving multiple jurisdictions. The scope encompasses branded and generic pharmaceutical line items with specific strength, dosage form, packaging, and National Drug Code (NDC) requirements, typically supplied through authorized wholesalers or direct-to-manufacturer relationships. Issuing bodies include city purchasing departments (fire rescue and emergency services), state health and human services commissions managing pharmacy benefits, and multistate cooperative purchasing organizations administering contracts across member jurisdictions.

Recent activity shows the City of Tampa Fire Rescue issuing an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials—a $40,000 contract with a Small Local Business Enterprise sheltered-market designation and a 5 percent bid discount—due April 8, 2026. The Texas Health and Human Services Commission posted an RFI in March 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for state-level pharmacy benefit contracting. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across member states including Oregon, with responses due March 26, 2026 and contract effectiveness July 1, 2026, requiring vendors to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson. Activity is concentrated in Texas, Minnesota and its MMCAP members, and Florida, with procurement spanning emergency services, state benefits programs, and cooperative purchasing vehicles.